Clinical Experts To Oversee Phase 3 Program of CGT-2168
MENLO PARK, Calif., Feb. 8 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc., today named a distinguished international panel of medical experts to serve on the Scientific Steering Committee charged with overseeing COGENT, the company's global Phase 3 clinical trial program for its novel combination antiplatelet product CGT-2168.
The panel includes experts in the fields of cardiology,
gastroenterology and clinical investigation. "We are extremely pleased that
these accomplished clinical scientists will advise us on the COGENT
program. Their participation will help ensure its scientific success," said
Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D.,
Members of the COGENT Scientific Steering Committee are:
-- Dr. Deepak Bhatt, Associate Director, Cardiovascular Coordinating
Center, Cleveland Clinic, Cleveland, Ohio
-- Dr. Marc Cohen, Director of the Division of Cardiology, Newark Beth
Israel Medical Center, Newark, New Jersey
-- Dr. Byron Cryer, John C. Vanatta III Professor of Medicine and
Associate Dean for Minority Affairs, Southwestern Medical School,
-- Dr. Angel Lanas, Service of Gastroenterology, University Hospital,
-- Dr. Thomas Schnitzer, Professor of Medicine, Division of Rheumatology,
Northwestern University Feinberg School of Medicine, Chicago, Illinois
The Scientific Steering Committee will be responsible for providing scientific and clinical oversight and advice to ensure the data that emerge from the COGENT program are of the highest quality and that the highest level of scientific conduct is maintained.
The ongoing COGENT program will evaluate the ef
|SOURCE Cogentus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved